市場調查報告書
商品編碼
1134949
更年期熱潮紅的全球市場規模調查&預測,各治療類型,各地區分析,2022-2029年Global Menopausal Hot Flashes Market Size study & Forecast, by Treatment Type (Hormonal Treatment and Non-hormonal Treatment) and Regional Analysis, 2022-2029 |
更年期潮熱通常是由伴隨女性更年期的雌激素水平下降導致的複雜荷爾蒙調整引起的。
對更年期及其治療的認識提高以及越來越多的支持膳食補充劑益處的研究等關鍵因素正在推動市場增長。
本調查的目的是定義近年來各個細分市場和國家的市場規模,並在未來幾年預測它們的價值。本報告設計內容涵蓋調查對象國家產業的定性和定量雙方面。
此外也提供市場未來性的成長促進因素和課題等重要方面相關之詳細資訊。再加上主要企業的競爭情形和提供產品之詳細分析,並涵括利害關係者投資所需的微觀市場潛在機會。詳細的市場區隔和子區隔如下列。
各治療類型
非荷爾蒙治療
荷爾蒙治療
各地區
北美
美國
加拿大
歐洲
英國
德國
法國
西班牙
義大利
其他歐洲
亞太地區
中國
印度
日本
澳洲
韓國
其他亞太地區
南美
巴西
墨西哥
全球其他地區
Global Menopausal Hot Flashes Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than 3.4% over the forecast period 2022-2029. Menopausal hot flashes are often brought on by the intricate hormonal adjustments brought on by the lowering oestrogen levels as menopause occurs in women. The body feels warm because of declining levels' effects on thermoregulation. On average, the illness can persist over 7 years, and in the most severe cases, it can last up to 10 years. Although it is a normal condition, it can be brought on by factors like drinking alcohol, eating hot food, smoking, being stressed, and other things. The market growth is driven by key factors such as increasing awareness about menopause and its treatment and increasing research supporting advantages of dietary supplements.
In the United States, roughly 1.3 million women cease menstruation each year, beginning between the ages of 51 and 52, according to the February 2022 version of "Menopause (Nursing)" by Kimberly Peacock et al. About 5% of women between the ages of 40 and 45 undergo early menopause, according to the same source. The market is also expanding as a result of the growing emphasis on research aimed at the development of treatments for hot flashes. For instance, Acer Therapeutics Inc. received FDA approval for its investigational new drug (IND) application for its selective non-peptide neurokinin 3 receptors (NK3R) antagonist, ACER-801 (osanetant), for the possible treatment of induced Vasomotor Symptoms in December 2021. (iVMS). However, side Effects Associated with Hormonal Products stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Menopausal Hot Flashes Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the overall market share owing to increased incidence of menopause and presence of a large percentage of older women in the region. However, Asia Pacific is expected to be the fastest growing region due to increased medical tourism and growing public awareness in the region.
Major market players included in this report are:
Bristol-Myers Squibb Company
Novartis AG
Teva Pharmaceutical Industries Ltd
Hisamitsu Pharmaceutical Co. Inc.
AstraZeneca PLC
Agile Therapeutics
Novo Nordisk Corporation
Pfizer Inc.
Merck & Co. Inc.
Ferring BV
Recent Developments in the Market:
Global Menopausal Hot Flashes Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Treatment Type, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment Type:
Non-hormonal Treatment
Hormonal Treatment
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable